EaglePicher Medical Power Introduces New Contego 440 mAh Lithium-ion Battery

New Contego® 440: An Implantable & Rechargeable Large-capacity, Small-footprint Cell Utilizing a Proven Chemistry that Has Extensive Cycling Data Across Multiple Medical Customers

EaglePicher® Medical Power, a division of EaglerPicher Technologies, announced today the launch of the all-new Contego® 440 mAh battery, an implantable grade, lightweight, and high-energy-density lithium-ion battery.

According to EaglePicher, the rechargeable off-the-shelf Contego 440 offers superior rate capability and cycle life and is manufactured in a certified ISO13405 facility.

The Contego 440 battery comes in a fully welded hermetically sealed stainless-steel case and can be used across a range of medical applications including neuromodulators, drug pumps, body fluid pumps, and cardiac monitors. The individual battery weighs just 19.1g and carries a voltage range of 3.0 to 4.1V. While the Contego 440 is available off-the-shelf, additional options include custom terminations, application-specific documentation for FDA submission, application-specific testing, custom markings, and custom packaging.

“We’re extremely pleased to introduce the Contego 440 as part of our growing line of mission-critical medical device batteries,” commented Chris Huntington, EaglePicher Medical Power’s President. “The team at EaglePicher Medical Power is committed to developing the latest technology innovations to fuel medical advancement, treatment protocols and improve quality of life. With the new Contego 440, we’ve succeeded in delivering more energy in a small, lightweight cell, while never compromising safety.”

EaglePicher has been at the forefront of implantable medical-grade power solutions for over 25 years. The electrochemistry used in Contego lithium-ion batteries, since 2004, is proven in multiple cell sizes and is remarkably robust, without experiencing a single field failure. Over time, demand has grown for batteries like the new Contego 440, which can do more with less of a physical footprint.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.
The rehabilitation robotic glove is a training device that combines EMG electromyographic feedback and flexible robotics for patients with stroke or hand disabilities to train and repair dexterity.
Conformal Medical is actively enrolling patients in the CONFORM pivotal trial, evaluating the safety and efficacy of the CLAAS System compared to other commercially available LAAO devices. The prospective, multicenter, randomized controlled study will enroll approximately 1,600 patients.
“This should be welcome news for patient care teams because a greater prediction rate with fewer false alerts translates into more effective and efficient care,” said Corey Centen, founder, president, and chief technical officer at Bodyport. “What’s more, use of the Cardiac Scale and the Congestion Index is a seamless transition for clinicians and patients because it enhances, rather than replaces, the existing pathways built around weight monitoring. The lower alert rate should lead to workflow efficiencies because care teams—who are often feeling overly burdened by the large number of notifications and data flowing in—will spend less time responding to false alerts.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy